American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 475-485, September 2008

Antiproteinuric Response to Dual Blockade of the Renin-Angiotensin System in Primary Glomerulonephritis: Meta-analysis and Metaregression

  • Fausta Catapano, MD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
  • ,
  • Paolo Chiodini, MSc

      Affiliations

    • Chair of Biostatistics at Second University of Naples, Naples, Italy
  • ,
  • Luca De Nicola, MD, PhD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
  • ,
  • Roberto Minutolo, MD, PhD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
  • ,
  • Pasquale Zamboli, MD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
  • ,
  • Ciro Gallo, MD

      Affiliations

    • Chair of Biostatistics at Second University of Naples, Naples, Italy
  • ,
  • Giuseppe Conte, MD

      Affiliations

    • Nephrology Division at Second University of Naples-S.M.d.P. Incurabili Hospital-ASL Na1, Naples, Italy
    • Corresponding Author InformationAddress correspondence to Giuseppe Conte, MD, Cattedra di Nefrologia, Dip Gerontologia, Geriatria, Mal Metabolismo, Seconda Università di Napoli, Piazza Miraglia, 80138 Napoli, Italia

Received 31 October 2007; accepted 3 March 2008. published online 13 May 2008.

Background

In patients with primary glomerulonephritis (GN), antiproteinuric response to angiotensin-converting enzyme (ACE) inhibitors plus angiotensin receptor blockers (ARBs) versus either monotherapy is undefined because of the small size of studies and high heterogeneity of response.

Study Design

Meta-analysis/metaregression.

Setting & Population

Randomized clinical trials (RCTs).

Selection Criteria for Studies

RCTs published from January 1996 to April 2007. Studies were excluded if information about levels of proteinuria was not available, patients had kidney disease other than primary GN, or if they had end-stage renal disease.

Intervention

ACE inhibitor plus ARB versus monotherapy with 1 of these drug classes.

Outcomes

Absolute changes in proteinuria (primary), blood pressure, serum potassium level, and glomerular filtration rate (GFR; secondary).

Results

We found 13 RCTs including 425 patients with primary GN with proteinuria ranging from 0.8 to 7.9 g/d of protein and age from 25 to 60 years. Combination treatment decreased proteinuria by 0.60 g/d (95% confidence interval, 0.40 to 0.80) versus ACE-inhibitor monotherapy and 0.54 g/d (95% confidence interval, 0.30 to 0.78) versus ARB monotherapy. Baseline levels of proteinuria explained most between-study variability of the antiproteinuric response to combination therapy versus monotherapies. Systolic and diastolic blood pressure, GFR, age, and diagnosis of immunoglobulin A nephropathy did not modify antiproteinuric response. ACE-inhibitor plus ARB therapy did not change GFR, whereas it increased serum potassium levels (by 0.10 mEq/L versus ACE-inhibitor and 0.19 mEq/L versus ARB therapy) and decreased blood pressure.

Limitations

Only published data are included.

Conclusions

The antiproteinuric response to ACE-inhibitor plus ARB therapy versus either monotherapy is consistently greater and strictly related to baseline proteinuria, associated with only moderate increase in serum potassium levels, and not peculiar to immunoglobulin A nephropathy.

Index Words: Chronic kidney disease, proteinuria, angiotensin II, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Originally published online as doi:10.1053/j.ajkd.2008.03.008 on May 8, 2008.

PII: S0272-6386(08)00582-9

doi:10.1053/j.ajkd.2008.03.008

American Journal of Kidney Diseases
Volume 52, Issue 3 , Pages 475-485, September 2008